Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia? - BeiGene Medical Europe
 

Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?

 Back  View
Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?
    07/2021
 View

The expert panel answers questions from the audience on a range of topics related to Waldenström’s macroglobulinemia diagnosis and treatment selection.

 

Rating

Rate this resource

Related resources

Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
 Back